What is a MASH Drug? Understanding Treatments for Metabolic Dysfunction-Associated Steatohepatitis
•
3 min read
In 2024, the U.S. Food and Drug Administration (FDA) approved the first-ever drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a serious liver disease. A **MASH drug** is a medication specifically designed to treat this condition, which is characterized by fat buildup, inflammation, and scarring in the liver. The approval of these specialized treatments marks a significant advancement for millions affected by this progressive disease, who previously had limited therapeutic options.
